Ibramvibart Medicine 04 June 2026 Extended indication Monotherapy for preventive treatment of COVID-19 in adolescents, adults and elderly Therapeutic value Total cost Registration phase Clinical trials Product Active substance Ibramvibart Domain Infectious diseases Reason of inclusion New medicine (specialité) Main indication COVID-19 Extended indication Monotherapy for preventive treatment of COVID-19 in adolescents, adults and elderly Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Invivyd Portfolio holder Invivyd Mechanism of action Other Route of administration Intramuscular Therapeutical formulation Injection Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Recombinant humaan monoclonal IgG1λ antilichaam Registration Registration route Type of trajectory Particularity ATMP Submission date September 2026 Expected Registration October 2027 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Therapeutic value Substantiation Duration of treatment Frequency of administration Dosage per administration References NCT07298434 (DECLARATION) Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Indications off label use References Additional remarks Indication extension Indication extensions Indication extensions References Additional remarks Other information Additional remarks